Amgen (NASDAQ:AMGN) Stock Unloaded Rep. David Taylor

Representative David Taylor (R-Ohio) recently sold shares of Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on February 02nd, the Representative disclosed that they had sold between $1,001 and $15,000 in Amgen stock on January 29th. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SARDINIA READY MIX 401(K) – DAVE” account.

Representative David Taylor also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of Vertex Pharmaceuticals (NASDAQ:VRTX) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Medpace (NASDAQ:MEDP) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Salesforce (NYSE:CRM) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Installed Building Products (NYSE:IBP) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Prologis (NYSE:PLD) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of JPMorgan Chase & Co. (NYSE:JPM) on 1/29/2026.

Amgen Price Performance

AMGN opened at $338.59 on Wednesday. The company has a market capitalization of $182.32 billion, a P/E ratio of 26.17, a PEG ratio of 3.03 and a beta of 0.46. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $353.25. The company has a 50-day moving average of $332.76 and a 200-day moving average of $310.04. The company has a debt-to-equity ratio of 5.45, a quick ratio of 0.99 and a current ratio of 1.28.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The company had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. During the same quarter last year, the firm earned $5.31 EPS. The business’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be given a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend is Friday, February 13th. This is an increase from Amgen’s previous quarterly dividend of $2.38. Amgen’s payout ratio is presently 73.57%.

Insider Buying and Selling

In other Amgen news, EVP Murdo Gordon sold 6,879 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the completion of the transaction, the executive vice president directly owned 41,923 shares in the company, valued at $14,120,924.09. The trade was a 14.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Nancy A. Grygiel sold 3,139 shares of the stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the transaction, the senior vice president directly owned 7,225 shares of the company’s stock, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 10,908 shares of company stock valued at $3,674,966. Company insiders own 0.69% of the company’s stock.

Analyst Ratings Changes

AMGN has been the subject of a number of recent research reports. Daiwa Capital Markets upped their price objective on Amgen from $310.00 to $370.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 18th. Oppenheimer set a $400.00 price objective on shares of Amgen and gave the stock an “outperform” rating in a report on Thursday, January 29th. UBS Group lifted their price objective on shares of Amgen from $380.00 to $390.00 and gave the company a “buy” rating in a research report on Monday, January 26th. HSBC reaffirmed a “buy” rating and set a $425.00 price target on shares of Amgen in a report on Wednesday, December 10th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Amgen in a report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Amgen presently has a consensus rating of “Moderate Buy” and a consensus price target of $342.45.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q4 results beat expectations — Amgen reported $5.29 EPS vs. consensus $4.76 and revenue of $9.87B vs. $9.46B; revenue rose ~8.6% YoY, driven by higher drug volumes. AMGEN Reports Fourth Quarter and Full Year 2025 Financial Results (Press Release/Slides)
• Positive Sentiment: Analysts and media note the quarter beat Street estimates on higher sales and a lower effective tax rate — items that helped EPS performance. Reuters: Amgen quarterly results beat Street estimates
• Neutral Sentiment: FY‑2026 guidance was reiterated/updated to an EPS range of 21.600–23.000 and revenue guidance roughly $37.0B–$38.4B; the range overlaps consensus but is wide, which may leave investors wanting clearer directional guidance.
• Neutral Sentiment: Market commentary and conference coverage remain generally constructive on Amgen’s pipeline and longer‑term prospects (e.g., positive remarks from commentators at the JPMorgan Healthcare Conference), supporting medium‑term fundamentals. Jim Cramer / Pipeline Commentary
• Negative Sentiment: Some of the reported earnings strength reflected lower net unrealized losses on equity investments and a lighter tax burden rather than pure operational margin expansion; that can temper how investors value the beat relative to recurring cash‑earnings. WSJ: Amgen logs higher Q4 revenue, lower unrealized losses
• Negative Sentiment: Broader market dynamics — rotation out of certain sectors and post‑earnings profit‑taking — likely amplified the selloff despite the beat; trading volumes were elevated on the move. Zacks: Markets rotate back out of tech after Q4 earnings

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of AMGN. Anfield Capital Management LLC lifted its holdings in Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after buying an additional 70 shares in the last quarter. Board of the Pension Protection Fund bought a new position in Amgen during the 4th quarter worth approximately $26,000. Legacy Investment Solutions LLC bought a new position in shares of Amgen during the second quarter worth $27,000. Evelyn Partners Investment Management LLP acquired a new stake in shares of Amgen during the second quarter worth $32,000. Finally, Howard Hughes Medical Institute bought a new stake in Amgen in the 2nd quarter valued at $32,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.

David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.